Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
29 pending office actions • 12 art units • 28 examiners • 0 of 29 (0%) have an AI response strategy ready • 24 patents granted in the last 365 days
Roche Sequencing Solutions Inc. currently manages 28 pending office actions within the Biotechnology & Pharmaceuticals technology area. This workload is distributed across 12 distinct art units. The portfolio involves 27 distinct examiners, which suggests that prosecution strategies must account for a variety of individual examiner preferences. The number of 27 distinct examiners relative to the 28 pending office actions means that almost every case is being reviewed by a different person. The 12 distinct art units represent the various technical divisions overseeing the applications.
Robert Thomas Crow is identified as the busiest examiner for this portfolio, currently handling 2 pending office actions. The volume of pending office actions is distributed across the various art units. The presence of the distinct examiners limits the ability to develop examiner-specific rapport across the majority of the pending cases, requiring the legal team to adapt to many different examination styles simultaneously. The 2 pending actions for the busiest examiner represent the highest concentration of cases under an individual.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 6 (21%) |
| §103 only | 2 (7%) |
| §112 only | 2 (7%) |
| Double-patenting only | 2 (7%) |
| Double-patenting + other | 5 (17%) |
| Multi-statute (no §101) | 12 (41%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CROW, ROBERT THOMAS | 2 | 41.7% | +32.7% |
| QIAN, SHIZHI | 1 | 61.8% | +47.9% |
| KAUR, GURPREET | 1 | 65.2% | +35.9% |
| SWIFT, CANDICE LEE | 1 | 57.5% | +36.0% |
| GIERE, REBECCA M | 1 | 73.7% | +32.3% |
| BUCCINI, MICHELLE CALLAHAN | 1 | — | — |
| LAU, JONATHAN S | 1 | 63.7% | -17.3% |
| BELLAH, JEFFREY LAWRENCE | 1 | 100.0% | +0.0% |
| KIM, YOUNG J | 1 | 64.8% | +18.1% |
| GREENE, CAROLYN LEE | 1 | 65.3% | +47.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17805511 | COMPUTING DEVICE WITH IMPROVED USER INTERFACE FOR INTERPRETING AND VISUALIZING DATA | ANDERSON-FEARS, KEENAN NEIL | 32d overdue |
| 18214232 | TUNNELING JUNCTIONS FOR SEQUENCING | WALLENHORST, MAUREEN | 3d overdue |
| 18052337 | MODULAR NUCLEIC ACID ADAPTERS | BUNKER, AMY M | 33d |
| 18962946 | DIFFERENTIAL OUTPUT OF ANALOG MEMORIES STORING NANOPORE MEASUREMENT SAMPLES | KAUR, GURPREET | — |
| 18580302 | ALPHA-HEMOLYSIN VARIANTS FORMING NARROW CHANNEL PORES AND USES THEREOF | BUCCINI, MICHELLE CALLAHAN | — |
| 18542500 | NUCLEOSIDE-5'-OLIGOPHOSPHATES HAVING A CATIONICALLY-MODIFIED NUCELOBASE | LAU, JONATHAN S | — |
| 18535222 | MOLECULAR DETECTION AND COUNTING USING NANOPORES | BELLAH, JEFFREY LAWRENCE | — |
| 18561986 | ENHANCER OLIGONUCLEOTIDES FOR NUCLEIC ACID HYBRIDIZATION | KIM, YOUNG J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19049948 | NANOPORE-BASED SEQUENCING WITH VARYING VOLTAGE STIMULUS | QIAN, SHIZHI | — |
| 18962946 | DIFFERENTIAL OUTPUT OF ANALOG MEMORIES STORING NANOPORE MEASUREMENT SAMPLES | KAUR, GURPREET | — |
| 18712051 | THERMOSTABLE POLYMERASE VARIANTS | SWIFT, CANDICE LEE | — |
| 18612744 | NANOPORE BASED MOLECULAR DETECTION AND SEQUENCING | GIERE, REBECCA M | — |
| 18420048 | CONCENTRATING A TARGET MOLECULE FOR SENSING BY A NANOPORE | CROW, ROBERT THOMAS | — |
| 18561986 | ENHANCER OLIGONUCLEOTIDES FOR NUCLEIC ACID HYBRIDIZATION | KIM, YOUNG J | — |
| 18475498 | IMMUME CELL COUNTING BASED ON IMMUNE REPERTOIRE SEQUENCING | GREENE, CAROLYN LEE | — |
| 18348235 | TRANSLOCATION CONTROL FOR SENSING BY A NANOPORE | CROW, ROBERT THOMAS | — |
| Art Unit | Apps |
|---|---|
| 1682 | 4 |
| 1681 | 4 |
| 1795 | 3 |
| 1683 | 3 |
| 1684 | 3 |
| 1687 | 2 |
| 1657 | 1 |
| 1693 | 1 |
| 1691 | 1 |
| 1797 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19049948 | NANOPORE-BASED SEQUENCING WITH VARYING VOLTAGE STIMULUS | QIAN, SHIZHI | 1795 | §112 | Non-Final OA | — | Pending | Feb 10, 2025 |
| 18962946 | DIFFERENTIAL OUTPUT OF ANALOG MEMORIES STORING NANOPORE MEASUREMENT SAMPLES | KAUR, GURPREET | — | §102§103 | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18712051 | THERMOSTABLE POLYMERASE VARIANTS | SWIFT, CANDICE LEE | 1657 | §102§112DP | Non-Final OA | — | Pending | May 21, 2024 |
| 18612744 | NANOPORE BASED MOLECULAR DETECTION AND SEQUENCING | GIERE, REBECCA M | — | DP | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18420048 | CONCENTRATING A TARGET MOLECULE FOR SENSING BY A NANOPORE | CROW, ROBERT THOMAS | 1682 | §112DP | Non-Final OA | — | Pending | Jan 23, 2024 |
| 18580302 | ALPHA-HEMOLYSIN VARIANTS FORMING NARROW CHANNEL PORES AND USES THEREOF | BUCCINI, MICHELLE CALLAHAN | 1682 | §102§112Other | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18542500 | NUCLEOSIDE-5'-OLIGOPHOSPHATES HAVING A CATIONICALLY-MODIFIED NUCELOBASE | LAU, JONATHAN S | 1693 | §102§103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18535222 | MOLECULAR DETECTION AND COUNTING USING NANOPORES | BELLAH, JEFFREY LAWRENCE | 1683 | §101§103DP | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18561986 | ENHANCER OLIGONUCLEOTIDES FOR NUCLEIC ACID HYBRIDIZATION | KIM, YOUNG J | 1681 | §102§103§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18475498 | IMMUME CELL COUNTING BASED ON IMMUNE REPERTOIRE SEQUENCING | GREENE, CAROLYN LEE | 1681 | §112 | Non-Final OA | — | Pending | Sep 27, 2023 |
| 18465724 | TARGETED NEXT-GENERATION SEQUENCING VIA ANCHORED PRIMER EXTENSION | BROWN, MINDY G | 1683 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 12, 2023 |
| 18279319 | DEVICES AND METHODS FOR ELECTROPHORETIC EXTRACTION OF NUCLEIC ACIDS FROM BIOLOGICAL SAMPLES | DEES, NIKKI H | 1691 | §102§103 | Non-Final OA | — | Pending | Aug 29, 2023 |
| 18348235 | TRANSLOCATION CONTROL FOR SENSING BY A NANOPORE | CROW, ROBERT THOMAS | 1682 | §102§112DP | Final Rejection | — | Pending | Jul 06, 2023 |
| 18215555 | Immuno-PETE | BOESEN, CHRISTIAN C | — | DP | Non-Final OA | — | Pending | Jun 28, 2023 |
| 18214232 | TUNNELING JUNCTIONS FOR SEQUENCING | WALLENHORST, MAUREEN | 1797 | §103§112 | Final Rejection | 3d overdue | Pending | Jun 26, 2023 |
| 18246009 | DEVICES AND METHODS FOR URINE SAMPLE ANALYSIS | SUN, CAITLYN MINGYUN | 1795 | §103 | Non-Final OA | — | Pending | Mar 20, 2023 |
| 18113308 | DEEP-LEARNING-BASED TECHNIQUES FOR GENERATING A CONSENSUS SEQUENCE FROM MULTIPLE NOISY SEQUENCES | FONSECA LOPEZ, FRANCINI ALVARENGA | — | §101§102§103 | Non-Final OA | — | Pending | Feb 23, 2023 |
| 18058484 | NANOPORE CELL WITH SEAMLESS WORKING ELECTRODE AND METHODS OF FORMING THE SAME | GAMBLE JR, RANDALL LEE | 1795 | §103 | Non-Final OA | 138d overdue | Pending | Nov 23, 2022 |
| 18052337 | MODULAR NUCLEIC ACID ADAPTERS | BUNKER, AMY M | 1684 | §102§112 | Non-Final OA | 33d | Pending | Nov 03, 2022 |
| 18051619 | SYSTEMS AND METHODS FOR USING TRAPPED CHARGE FOR BILAYER FORMATION AND PORE INSERTION IN A NANOPORE ARRAY | SCHLOOP, ALLISON ELIZABETH | 1683 | §103§112 | Non-Final OA | — | Pending | Nov 01, 2022 |
| 17922222 | A METHOD FOR DETECTING REACTION VOLUME DEVIATIONS IN A DIGITAL POLYMERASE CHAIN REACTION | SANFORD, DIANA PATRICIA | 1687 | §101§103§112 | Non-Final OA | — | Pending | Oct 28, 2022 |
| 17905784 | NOVEL NUCLEIC ACID TEMPLATE STRUCTURE FOR SEQUENCING | GIAMMONA, FRANCESCA FILIPPA | 1681 | §102§103 | Non-Final OA | — | Pending | Sep 07, 2022 |
| 17856923 | CHEMICAL METHODS FOR PRODUCING TAGGED NUCLEOTIDES | ZHANG, KAIJIANG | 1684 | §102§103 | Non-Final OA | — | Pending | Jul 01, 2022 |
| 17805511 | COMPUTING DEVICE WITH IMPROVED USER INTERFACE FOR INTERPRETING AND VISUALIZING DATA | ANDERSON-FEARS, KEENAN NEIL | 1687 | §101§103 | Final Rejection | 32d overdue | Pending | Jun 06, 2022 |
| 17756068 | SYSTEMS AND METHODS FOR CONTAMINATION DETECTION IN NEXT GENERATION SEQUENCING SAMPLES | SMITH, EMILIE ALINE | 1686 | §101§112 | Non-Final OA | — | Pending | May 16, 2022 |
| 17651135 | SINGLE TUBE PREPARATION OF DNA AND RNA FOR SEQUENCING | YU, TIAN NMN | 1681 | §102§103 | Non-Final OA | — | Pending | Feb 15, 2022 |
| 17561626 | INCREASING DYNAMIC RANGE FOR IDENTIFYING MULTIPLE EPITOPES IN CELLS | YOUNG, BRIAN ELLIS | 1684 | §112DP | Final Rejection | 49d overdue | Pending | Dec 23, 2021 |
| 17595263 | DEVICES AND METHODS FOR SAMPLE ANALYSIS | DAUNER, JOSEPH G | 1682 | §103DP | Final Rejection | 46d overdue | Pending | Nov 12, 2021 |
| 17350822 | METHODS FOR DETECTING AN ANALYTE USING STRUCTURE SWITCHING BINDING AGENTS | NGUYEN, BAO THUY L | 1677 | §102§103 | Final Rejection | — | Pending | Jun 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial